New drug duo aims to hold deadly pancreatic cancer at bay
NCT ID NCT06747845
Summary
This study is testing whether a combination of two drugs, niraparib and ipilimumab, can help keep metastatic pancreatic cancer from getting worse in people whose disease has stabilized after initial chemotherapy. It will compare this two-drug approach to standard chemotherapy. The main goal is to see if the new combination can extend the time before the cancer progresses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania, Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.